REINACH, Switzerland, December 19 /PRNewswire-FirstCall/ -- Arpida Ltd. announces positive top-line data of the Phase II ‘intravenous-to-oral’ switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).
The top-line results demonstrated high clinical cure rates of over 90% following the step-down therapy with oral iclaprim administered after two days of initial treatment with intravenous vancomycin. In the Per Protocol population 27/29 patients in the oral iclaprim arm were cured, as compared to 28/28 following continuous treatment with intravenous vancomycin. Eradication rates for S. aureus, the major causative pathogen, were high with 85% in the oral iclaprim arm, and similar to intravenous vancomycin (89%). Iclaprim was well tolerated; adverse events were infrequent and not significantly different between both study arms. Importantly, no drug-related serious adverse events occurred and there were no patient withdrawals due to adverse events.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
This statement was also released in German and French. The English original is the binding version.
CONTACT: Arpida contacts: Dr Jurgen Raths, President and CEO, Tel:
+41-61-417-96-60. Harry Welten, MBA, CFO and Senior Vice President, Tel:
+41-61-417-96-65. Paul Verbraeken, Head of Corporate Communications, Tel:
+41-61-417-96-83.
